Clinical trial · Observational
Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Molecular Testing Panel in the Community Setting ("DINOSAur")
NCT05692466CI-TRIAL-00064417DINOSAurunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage III Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
| Stage IV Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Comprehensive molecular panel test | Diagnostic Test | — | UNRESOLVED |
| EORTC QLQ-30 | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Active
- description
- Newly diagnosed cancer patients.
- interventionNames
- Diagnostic Test: Comprehensive molecular panel test
- Other: EORTC QLQ-30
- label
- Control
- description
- Historically diagnosed cancer patients.
Primary outcomes (1)
- measure
- European Organization for Research and Treatment of Cancer quality of life Questionnaire-C30 (QLQ-C30)
- timeFrame
- 2 years
- description
- The EORTC Core Questionnaire (QLQ-C30) includes six clearly distinguishable functioning scales that have been thoroughly tested and validated on an international level and that are available in 110 different language versions.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who have given informed consent in accordance with the methods and procedures of this study * Diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care * Patients who have not received treatment related to his/her cancer * Patients who are willing to sign a release of medical records to the research team * Male and female patients ≥18 years of age * Patients under oncology care of a participating site * Sufficient clinical status for collection of biospecimen samples within usual care * Patients who have insurance coverage for CMT Exclusion Criteria: * Patients considered minors in the jurisdiction where the protocol is conducted. * Patients who are prisoners and pregnant women. * Patients who cannot provide consent and did not sign a power of attorney.
References
Publications (0)
Data not yet available
No reference posted for this study.